secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001680367-25-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1
------------------------------------------------------------------------------

- Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.
- Net loss Q4 2024 $18.7M ($0.37/share) vs $17.7M ($0.41) Q4 2023; FY loss $75.4M vs $87.3M.
- R&D expenses $15.4M Q4; full year $67.2M down from $74.3M due to termination of SL-172154 program.
- SL-325 DR3 blocking antibody on track for IND filing in Q3 2025; Phase 1 enrollment expected complete Q2 2026.
- Preclinical NHP data at ECCO showed favorable safety, full receptor occupancy, no DR3 agonism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/0001680367-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/sttk-20250327.htm
  HTML page:      https://secwatch.observer/filing/0001680367-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer